Pluristem Therapeutics (PSTI)'s Manufacturing Facility Approved By European Auditors For Phase 3 Trials
4/28/2014 8:52:38 AM
HAIFA, Israel, April 28, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its new manufacturing facility has received the European Union's Qualified Person Declaration. With this declaration, Pluristem is now approved to use cell therapies manufactured at its state-of-the-art facility located in Haifa, Israel, in all phases of its clinical trials conducted in the European Union, including Phase I, Phase II and Phase III.
Help employers find you! Check out all the jobs and post your resume.
comments powered by